Appeals Court Upholds Ruling Favoring Transkaryotic in Patent Suit
Only a day earlier, Genzyme Corp. pulled out of the litigation as part of a settlement. Genzyme and Mount Sinai School of Medicine claimed that Transkaryotic's main product, Replagal, infringed on one of their patents.
A Delaware district court dismissed the lawsuit in January 2002, and Genzyme and Mount Sinai appealed the decision in March of that year.
As part of the...
To view the full article, register now.